apo-go pfs solution for infusion 5mg/ml
britannia pharmaceuticals limited - apomorphine hydrochloride - solution for infusion - apomorphine hydrochloride 5 mg/ml - anti-parkinson drugs
apo-go pen solution for injection 10mg/ml
britannia pharmaceuticals limited - apomorphine hydrochloride - solution for injection - apomorphine hydrochloride 10 mg/ml - anti-parkinson drugs
apomorphine wockhardt apomorphine hydrochloride hemihydrate 10 mg/ml solution for injection or infusion ampoule
wockhardt bio pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium hydroxide; hydrochloric acid; water for injections - apomorphine wockhardt solution for injection or infusion is indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.
apo-go
abic marketing ltd, israel - apomorphine hydrochloride - solution for injection / infusion - apomorphine hydrochloride 10 mg/ml - apomorphine - apomorphine - treatment of motor fluctuations (“on-off” phenomena) in patients with parkinson's disease which are not sufficiently controlled by oral anti-parkinson medication.
apo go pen 10 mgml
teva israel ltd - apomorphine hydrochloride - solution for injection - apomorphine hydrochloride 10 mg/ml - apomorphine - apomorphine - treatment of motor fluctuations (“on-off” phenomena) in patients with parkinson's disease which are not sufficiently controlled by oral anti-parkinson medication.
apomine apomorphine hydrochloride hemihydrate 100 mg/20 ml solution for infusion vial
interpharma pty ltd - apomorphine hydrochloride hemihydrate, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium chloride; hydrochloric acid; water for injections - indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.
movapo pfs apomorphine hydrochloride hemihydrate 50mg/10ml solution for subcutaneous infusion pre-filled syringe
stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 50 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; hydrochloric acid - movapo pfs is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine injection should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.
apo-go pfs 5mg/ml solution for infusion in pre-filled syringe
stada arzneimittel ag stadastraße 2-18, 61118 bad vilbel, germany - apomorphine hydrochloride - solution for infusion - apomorphine hydrochloride 5 mg/ml - anti-parkinson drugs
apo-go pen 10mg/ml solution for injection
stada arzneimittel ag stadastraße 2-18, 61118 bad vilbel, germany - apomorphine hydrochloride - solution for injection in a pre-filled pen - apomorphine hydrochloride 10 mg/ml - anti-parkinson drugs
apo-go pod 5 mg/ml solution for infusion in cartridge
stada arzneimittel ag - apomorphine hydrochloride hemihydrate - solution for infusion in cartridge - 5 milligram(s)/millilitre - apomorphine